

**Modern approaches and recent achievements  
in studying the impact of white lupin seed  
proteins on human nutrition and health**

**Marcello Duranti**  
**Department of AgriFood Molecular Sciences**  
**Faculty of Agriculture**  
**University of Milan, Italy**

**DI**partimento  
**S**cienze  
**M**olecolari  
**A**groalimentari



# Agricultural and Nutritional Aspects of Lupines

Proceedings of the First International Lupine Workshop

Lima - Cuzco, Peru  
12 – 21, April 1980

R. Gross and E. S. Bunting

Eschborn 1982

CHEMICAL, NUTRITIONAL AND FUNCTIONAL PROPERTIES OF  
LUPINE SEED PROTEINS

P. Cerletti, M. Duranti and P. Restani

Department of General Biochemistry, University of Milan,  
Milano, Italy

# Claims on legume seed beneficial properties

American Heart Association (AHA) dietary indications:

...diet should “contain a variety of foods from all the food categories”; emphasis should be given to “fruits and vegetables, fat-free and low-fat dairy products, cereal and grain products, **legumes** and nuts, fish, poultry, and lean meats”. (J Nutr 2001;131:132)

Other scientific board claims:

“**Grain legumes** effectively contribute to a balanced diet and can prevent widely diffused diseases, including type II diabetes and cardiovascular diseases”. (Br J Nutr 2002; 88 Suppl 3:239)

# Metabolic fate of dietary proteins

## Established facts:

- ✓ Dietary proteins are the source of amino acid for the body
- ✓ Proteins are normally degraded to amino acids by proteases during the digestion processes in the gastro-intestinal tract

## Open issues:

- ✓ Digestion of proteins can be incomplete
- ✓ Full-length proteins or their fragments may play various local and systemic effects

## Content of the presentation

- ✓ Do lupin seed proteins have an impact beyond dietary supply of amino acids?
- ✓ How molecular nutraceuticals does help in understanding lupin seed protein role
- ✓ Case-studies of selected white lupin seed proteins
- ✓ Concluding remarks

# Summary of *Lupinus albus* conglutins' main features

<i>Congl.</i>	<i>Protein family</i>	<i>% of total globulin</i>	<i>Native protein</i>			<i>Monomer composition</i>				<i>Protein function in the seed</i>
			<i>M<sub>r</sub>, kDa</i>	<i>pI</i>	<i>Quaternary structure</i>	<i>Subunit name</i>	<i>M<sub>r</sub>, kDa</i>	<i>pI</i>	<i>Glycosylation</i>	
$\alpha$	11S legumin	35-37	330-430	5.1-5.8	Hexamer	Acidic* Basic*	42-52 20-22	4.5-4.7 6.7-8.6	Yes/No <sup>1</sup> No	Storage
$\beta$	7S vicilin	44-45	143-260	5.0-6.0	Trimer	HMW IMW LMW	53-64 25-46 17-20	5.1-5.7 5.3-8.4 4.2-5.0	Yes Yes/No <sup>1</sup> Yes/No <sup>1</sup>	Storage
$\gamma$	7S	4-5	200	7.9	Tetramer	Large* Small*	29 17	8.2-8.9 5.8-6.6	Yes No	Unknown
$\delta$	2S	10-12	13	acidic	Monomer (dimer)	Large* Small*	9 4	4.1-4.3 n.d.	No No	Unknown



# The major proteins of lupin seed: Characterisation and molecular properties for use as functional and nutraceutical ingredients

Marcello Duranti\*,  
Alessandro Consonni,  
Chiara Magni, Fabio Sessa and  
Alessio Scarafoni

Department of Agri-Food Molecular Sciences,  
State University of Milan,  
Via G. Celoria 2, 20133 Milano,  
Italy


(Tel.: +39 02 50316817; fax: +39 02 50316801;  
e-mail: marcello.duranti@unimi.it)

## Introduction

The need for plant-derived nutrients is expected to grow due to economic and environmental factors as well as to support the development of new, safe and healthy foods which may respond to the consumers' increasing awareness of the impact of dietary habits on human well-being. Likewise, an increasing demand for plant proteins to be used as food ingredients for the improvement of nutritional, technological and healthy profiles of modern food is emerging, especially in more affluent countries. Although the "historical" role of several legume and cereal grains was as sources of oil for foods, interest in other seed components, including proteins, starches, fibres and minor constituents, is expanding in parallel with industrially available improved separation techniques.

Legume seeds are an abundant source of proteins and, among them, lupin is one of the richest. Indeed, lupin seed deserves greater interest as a result of its chemical composition and augmented availability in many countries in recent years. Lupin is a non-starch leguminous seed with a high protein content, almost as high as that of soybean (about 35% of the dry weight), and a relatively low oil content. Among the lupin seed species, the most cultivated, primarily in Australia, is blue lupin (*Lupinus angustifolius* L.), while the typical European and South American varieties are yellow (*Lupinus luteus* L.) and white (*Lupinus albus* L., Fig. 1) lupins. Blue and yellow lupin seeds are mostly used for feed, while the white lupins are primarily grown for food uses. For this reason, proteins from white lupin seeds will be the focus of this review.

## 2-D IEF/SDS-PAGE reference map of lupin seed proteome



# List of attributed spots in lupin seed proteome

Spot	Vol. %	Protein identification	Accession number	P-value	Score	Mr <sup>a</sup>	MW <sup>b</sup>	pI <sup>a</sup>	pI <sup>b</sup>	A.a. cov. <sup>c</sup> , %
10	0.44	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470 AA597865	4.7 x 10 <sup>-10</sup>	128	63,800	62,032	5.11	6.08	31.1
15	0.23	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470 AA597865	1.7 x 10 <sup>-11</sup>	140	64,400	62,130	5.67	6.43	33.8
22	0.64	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470 AA597865	6.4 x 10 <sup>-11</sup>	170	58,200	62,032	5.20	6.08	36.9
25	0.50	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470 AA597865	3.4 x 10 <sup>-11</sup>	168	59,400	62,032	5.42	6.08	37.9
29	0.14	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470	2.1 x 10 <sup>-14</sup>	200	60,883	62,032	5.59	6.08	42.0
32	0.11	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470 AA597865	6.4 x 10 <sup>-6</sup>	140	56,000	62,032	5.49	6.08	35.0
36	0.18	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470	2.8 x 10 <sup>-9</sup>	168	52,900	62,032	5.30	6.08	37.5
41	3.06	No identification				45,400		4.67		
43	0.25	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470 AA597865	2.2 x 10 <sup>-9</sup>	100	46,000	62,130	5.80	6.43	25.1
44	0.41	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470 AA597865	8.1 x 10 <sup>-11</sup>	98	45,886	62,130	6.13	6.43	21.8
46	1.30	No identification				44,200		4.50		
48	0.37	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470 AA597865	1.9 x 10 <sup>-10</sup>	180	44,000	62,032	5.40	6.08	41.1
50	1.25	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470 AA597865	6.5 x 10 <sup>-11</sup>	138	43,500	62,032	5.72	6.08	27.5
52	0.68	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470	2.5 x 10 <sup>-13</sup>	158	43,562	62,032	6.24	6.08	38.8
53	0.62	No identification				41,900		4.58		
55	0.23	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470	8.4x 10 <sup>-13</sup>	150	42,162	62,032	5.70	6.08	37.5
58	0.57	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470	7.4 x 10 <sup>-6</sup>	58		62,032		6.08	16.8
58	0.57	alcohol dehydrogenase	AAC62469	8.9 x 10 <sup>-9</sup>	28	42,036	42,241	6.50	6.09	8.6
60	3.73	α-conglutinin precursor ( <i>Lupinus albus</i> )	AJ938034	3.3 x 10 <sup>-7</sup>	50	38,500	60,792	4.58	5.90	13.1
65	0.61	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470 AA597865	1.2 x 10 <sup>-10</sup>	88	37,000	62,032	4.62	6.08	22.0
65	0.61	α-conglutinin precursor ( <i>Lupinus albus</i> )	AJ938034	6.7 x 10 <sup>-8</sup>	30	37,000	60,792	4.62	5.90	10.9
70	0.47	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470	1.6 x 10 <sup>-9</sup>	130	37,600	62,032	5.60	6.08	31.1
73	0.63	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470	1.8 x 10 <sup>-10</sup>	160	37,600	62,032	6.46	6.08	35.4
78	0.59	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470	2.6 x 10 <sup>-9</sup>	78	34,300	62,032	4.43	6.08	20.9
79	1.86	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470	1.7 x 10 <sup>-8</sup>	58	34,500	62,032	4.56	6.08	14.1
83	0.42	Putative TAG-associated factor ( <i>Lupinus angustifolius</i> )	AAN75426	3.5 x 10 <sup>-4</sup>	10	34,000	32,214	5.68	6.33	5.1
87	1.16	β-conglutinin precursor ( <i>Lupinus albus</i> )	AA597865	1.2 x 10 <sup>-11</sup>	110	32,900	62,130	6.59	6.43	24.3
89	1.28	γ-conglutinin precursor ( <i>Lupinus albus</i> )	CAC16394	1.4 x 10 <sup>-7</sup>	60	30,800	49,219	8.65	8.40	18.1
90	1.49	γ-conglutinin precursor ( <i>Lupinus albus</i> )	CAC16394	5.4 x 10 <sup>-6</sup>	60	30,900	49,219	8.85	8.40	23.0
90	1.49	β-conglutinin precursor ( <i>Lupinus albus</i> )	AA597865 AJ966470	1.1 x 10 <sup>-9</sup>	70	30,900	62,130	8.85	6.43	17.8
92	0.16	No identification				24,771		5.28		
93	0.30	α-conglutinin precursor ( <i>Lupinus albus</i> )	AJ938034	2.6 x 10 <sup>-8</sup>	30	23,600	60,792	5.36	5.90	14.1
96	0.20	α-conglutinin precursor ( <i>Lupinus albus</i> )	AJ938034	1.7 x 10 <sup>-8</sup>	40	23,200	60,792	5.71	5.90	14.4
97	2.17	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470	1.2 x 10 <sup>-8</sup>	28	20,400	62,032	4.33	6.08	7.2
98	2.37	β-conglutinin precursor ( <i>Lupinus albus</i> )	AA597865	1.2 x 10 <sup>-8</sup>	18	18,812	62,130	4.32	6.43	4.7
99	0.48	α-conglutinin precursor ( <i>Lupinus albus</i> )	AJ938034	6.3 x 10 <sup>-8</sup>	20		60,792		5.90	10.7
99	0.48	β-conglutinin precursor ( <i>Lupinus albus</i> )	AA597865	3.7 x 10 <sup>-7</sup>	50		62,130		6.43	8.6
101	0.37	small HSP ( <i>Retama roetama</i> )	AAL32036	1.3 x 10 <sup>-6</sup>	20	19,900	17,891	5.09	5.82	20.3
102	0.50	18.50kDa class I heat shock protein ( <i>Glycine max</i> )	P05478	1.2 x 10 <sup>-6</sup>	40	19,522	18,503	5.34	5.82	21.1
103	0.41	Legumin K ( <i>Pisum sativum</i> )	S26688	1.5 x 10 <sup>-7</sup>	10	19,700	56,276	6.67	5.65	2.8
104	0.77	Legumin K ( <i>Pisum sativum</i> )	S26688	6.9 x 10 <sup>-7</sup>	6	20,300	56,276	7.09	5.65	2.8
105	1.33	Legumin K ( <i>Pisum sativum</i> )	S26688	1.5 x 10 <sup>-7</sup>	10	20,300	56,276	7.85	5.65	2.8
106	0.87	Legumin K ( <i>Pisum sativum</i> )	S26688	6.5 x 10 <sup>-7</sup>	4	20,300	56,276	8.3	5.65	2.8
107	0.45	Legumin K ( <i>Pisum sativum</i> )	S26688	9.8 x 10 <sup>-7</sup>	8	20,500	56,276	8.57	5.65	2.8
110	0.29	γ-conglutinin precursor ( <i>Lupinus albus</i> )	CAC16394	1.1 x 10 <sup>-8</sup>	40	18,300	49,219	5.78	8.40	16.8
111	0.65	γ-conglutinin precursor ( <i>Lupinus albus</i> )	CAC16394	7.1 x 10 <sup>-14</sup>	70	18,900	49,219	6.21	8.40	24.6
112	1.35	γ-conglutinin precursor ( <i>Lupinus albus</i> )	CAC16394	1.2 x 10 <sup>-3</sup>	40	18,000	49,219	6.19	8.40	15.3
113	0.09	γ-conglutinin precursor ( <i>Lupinus albus</i> )	CAC16394	2.7 x 10 <sup>-10</sup>	30	18,900	49,219	6.57	8.40	14.4
114	0.17	γ-conglutinin precursor ( <i>Lupinus albus</i> )	CAC16394	6.0 x 10 <sup>-14</sup>	50	18,200	49,219	6.56	8.40	14.4
115	6.47	δ-conglutinin precursor ( <i>Lupinus albus</i> )	CAJ43922 CAJ42100	1.8 x 10 <sup>-5</sup>	30	17,300	17,138	4.21	5.47	26.4
115	6.47	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470	6.0 x 10 <sup>-8</sup>	30	17,300	62,032	4.21	6.08	7.2
117	0.38	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470	1.0 x 10 <sup>-8</sup>	68	16,500	62,032	4.56	6.08	17.7
118	0.69	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470	1.0 x 10 <sup>-14</sup>	100	16,818	62,032	4.73	6.08	19.6
121	0.21	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470	6.2 x 10 <sup>-10</sup>	70	16,400	62,032	5.2	6.08	17.9
121	0.21	γ-conglutinin precursor ( <i>Lupinus albus</i> )	CAC16394	1.3 x 10 <sup>-8</sup>	40		49,219		8.4	16.8
125	1.00	β-conglutinin precursor ( <i>Lupinus albus</i> )	AA597865 AJ966470	1.2 x 10 <sup>-5</sup>	20	30,996	62,032	8.35	6.08	5.1
126	0.62	γ-conglutinin precursor ( <i>Lupinus albus</i> )	CAC16394	3.8 x 10 <sup>-8</sup>	40		49,219		8.4	13.1
126	0.62	β-conglutinin precursor ( <i>Lupinus albus</i> )	AA597865 AJ966470	1.7 x 10 <sup>-3</sup>	100	32,438	62,032	8.19	6.43	22.3
127	0.89	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470 AA597865	1.6 x 10 <sup>-13</sup>	110	32,616	62,032	7.60	6.08	24
128	0.89	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470 AA597865	8.2 x 10 <sup>-12</sup>	100	32,682	62,032	7.08	6.08	22
130	0.27	No identification				26,657		5.62		
131	0.17	No identification				26,333		5.95		
132	0.22	β-conglutinin precursor ( <i>Lupinus albus</i> )	AJ966470 AA597865	8.6 x 10 <sup>-9</sup> 1.3 x 10 <sup>-4</sup>	20 10	26,467	62,032 24,414	6.37	6.08 6.08	22



Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

ScienceDirect

PHYTOCHEMISTRY

Phytochemistry 68 (2007) 997–1007

[www.elsevier.com/locate/phytochem](http://www.elsevier.com/locate/phytochem)


## Combined 2D electrophoretic approaches for the study of white lupin mature seed storage proteome

Chiara Magni<sup>a</sup>, Alessio Scarafoni<sup>a</sup>, Anita Herndl<sup>a,1</sup>, Fabio Sessa<sup>a</sup>,  
Bhakti Prinsi<sup>b</sup>, Luca Espen<sup>b</sup>, Marcello Duranti<sup>a,\*</sup>

<sup>a</sup> Department of Agrifood Molecular Sciences, State University of Milan, Via Celoria 2, 20133 Milano, Italy  
<sup>b</sup> Department of Crop Production, State University of Milan, Via Celoria 2, 20133 Milano, Italy

Received 28 November 2006; received in revised form 8 January 2007  
Available online 23 February 2007

# 2-D IEF/SDS-PAGE reference map of lupin seed proteome




## The original nutraceutical concept

Nutraceutical is “any food, or part of food, considered to provide health benefits, including the prevention and treatment of disease”

**Stephen De Felice, 1989**

“Let your food be your medicine and let your medicine be your food”

**Hippocrates (460-370 B.C.)**



# The “molecular nutraceuticals” concept

Individual target molecule analyses, involving:


- ✿ Isolation from the wild source  
(cloning/expression from suitable hosts)
- ✿ Molecular characterisation
- ✿ Biological activity measurements
- ✿ Elucidation of the mechanism(s)



## Case study 1:

# Blood glucose-controlling lupin protein: $\gamma$ -conglutin

**Figure 1** Numbers of people with diabetes (in millions) for 2000 and 2010 (top and middle values, respectively), and the percentage increase.  
 Data adapted from ref. 2.



# Glycemic control


Pulses are low GI foods in force of their starch peculiar composition. Thus, dry legumes are claimed to help glycemic control in diabetic individuals

Role of galattomannan-rich soluble dietary fibre and 4-hydroxyisoleucine (Broca et al., 2000)

$\alpha$ -amylase inhibitors have been claimed to play anti-diabetic effects (McKarty, 2005)

**Other causative agents?????**

# Binding of lupin $\gamma$ -conglutin to insulin-agarose


 ELSEVIER


REVIEWS: CURRENT TOPICS  
 THE JOURNAL OF  
 Nutritional  
 Biochemistry

Journal of Nutritional Biochemistry 15 (2004) 646–650


**Conglutin  $\gamma$ , a lupin seed protein, binds insulin in vitro and reduces plasma glucose levels of hyperglycemic rats**

Chiara Magni<sup>a</sup>, Fabio Sessa<sup>a</sup>, Elena Accardo<sup>b</sup>, Marco Vanoni<sup>b</sup>, Paolo Morazzoni<sup>c</sup>,  
 Alessio Scarafoni<sup>a</sup>, Marcello Duranti<sup>a,\*</sup>


<sup>a</sup>Department of AgriFood Molecular Sciences, University of Milan, Milan, Italy  
<sup>b</sup>Department of Biotechnology and Biosciences, University of Milan Bicocca, Milan, Italy  
<sup>c</sup>Scientific Department, INDENA S.p.A, Milan, Italy



# Surface Plasmon Resonance analysis of the interaction between $\gamma$ -conglutin and insulin



# Influence of $\gamma$ -conglutin on rat plasma glucose concentrations during glucose overloading trials



\*:  $P < 0.05$ , \*\*:  $P < 0.01$ , \*\*\*:  $P < 0.001$  vs. control

# Alignment of $\gamma$ -conglutin with wheat xylanase inhibitor, TAXI (30% identity)

```

c32      LYHNSQPTSSSKPNLLVLP IQQDASTK LHWGNI LKRTPLMQVPVLLDLNGKHLWVT SQH 60
TAXI     LPVLAPVTKDPATSLYTI PFHDGAS-----LVLDVAGPLVWSTQDGG 42
          *   :   *... ..*   .:~::~**          :~::~*   :*   **.

c32      YSSSTYQAPFCHSTQCSRANTHQCFTC TDS TTSRPGCHNNTCGLI SSNPVTQESGLGELA 120
TAXI     QPPAEIP---CSSPTQLLANAYPAPGCPAPSCG-SDKHDKPCTAYPYNPVSGA CAAGSLS 98
          ..:          * * . *   ***: .   * . .: . . . *~::~*   .   ***: .. *~::~*

c32      QDVLALHSTHGSKLGS LVKIPQFLFSCAPTFLTQKGLPNNVQGALGLGHAPISLPNQLFS 180
TAXI     HTRFVANTTDGSKPVSKVNVG-VLAAGAPSKLLAS-LPRGSTGVAGLANSGLALPAQVAS 156
          :   : . . :~::~*~::~*~::~*   *   *~::~*   :~::~*~::~*~::~*   *   *~::~*~::~*~::~*   :~::~*~::~*~::~*

c32      HFGLKRQFTMCLSSYPTSN GAILFGDINDPNNNNY IHNSLDVLDHDMVYTPLTISKQG-EY 239
TAXI     AQKVANRFLLC LPTG--GPGVAIFGGGPVWP-----QFTQSMPTPLVTKGGSPA H 206
          :   :~::~*~::~*~::~*~::~*~::~*   :   * . :~::~*~::~*   *   :   :~::~*~::~*~::~*~::~*~::~*   .   .   :


c32      FIQVSAIRVNKHMVIP TKNPSMFPSSSSSSSYHE SSEIGGAMITTTNPYTVLRHSIFEVFT 299
TAXI     YISARSIVVGDTRVPVPEG-----ALATGGVMLSTRLP-YVLLRPDVYRPLMDAF TKALA 260
          :~::~*~::~*   *   *   . . .   :   :~::~*~::~*~::~*~::~*~::~*   :~::~*~::~*   :~::~*   *   :~::~*~::~*~::~*

c32      QVFANNVPKQAQVKAVGPFGLCYDTKKISG-----GVPSVDLIMDKSDVVWRISGENLMV 354
TAXI     AQHANGAPVARAVEAVAPFGV CYDTKTLGNNLGGYAVPNVQLGLD-GGSDWTMTGKNSMV 319
          . * ~::~*~::~*   *~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*


c32      QAQDGVSLGFVDG-GVHTRAG----IALGTHQLEENLVVFDLARSRVGFNTNSLKSHGK 409
TAXI     DVKQGTACVAVFVEMKVAAGDGRAPAVILGGAQMEDFVLD FDM EKKRLGFSR---LPHFT 376
          :~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*~::~*

c32      SC SNLFDLNNP 420
TAXI     GCGGL----- 381
          . * ~::~*~::~*
  
```

# Comparison of the 3D structures of truncated $\gamma$ -conglutin and wheat xylanase inhibitor



Truncated TAXI 3D structure  
(PDB: 1T6G)



Truncated conglutin  $\gamma$  predictive model  
(Swiss-Model Repository)

# Further ongoing studies on $\gamma$ -conglutin bioactivities

- ✓ Caco2 cell transwell transfer analysis  
(Dr. Alfonso Clemente, CSIC, Granada, Spain)
- ✓ Effect of  $\gamma$ -conglutin on mioblast cell signalling pathways  
(Prof. Livio Luzi, Univ. Milano and San Raffaele Hospital, Milano)
- ✓ Clinical study on healthy and pre-diabetic human volunteers  
(INDENA and Drs. Hancke and Bertoglio, Un. Austral de Chile)

## Case study 2:

# Anticarcinogenic (?) lupin protein: Bowman-Birk Serine Protease Inhibitor

# Anti-carcinogenic effects of legume seed components

Compounds that have traditionally been considered beneficial:

- protease inhibitors;
- saponins;
- phytosterols;
- isoflavons;
- phytates;
- fibre and non-digestible starch

$\alpha$ -galactosides: prebiotic molecules that promote in the gut the growth of positive M.O. producing short fatty acids (butyric), protective against colon cancer. Positive M.O. also inhibit pathogen (Gaudard-De Weck, 1999).

Bowman-Birk inhibitor (BBI) family provided evidence to arrest some mammalian tumors (Kennedy, 1998).


# Anticancer activities of Bowman-Birk serine proteinase inhibitors from legume seeds

Animal model	Disease type	Carcinogen/ Chemical	Effective Protease inhibitor	Level of effect	Refs
Mouse	Liver cancer	Spontaneous DMH	0.01% BBI in diet 0.1% BBI in diet 0.5% BBI in diet	<b>100% fewer tumors</b> <b>50% fewer tumors</b> <b>75% fewer tumors</b>	[32] [10] [10]
	Colon cancer	DMH	0.1% BBI in diet 0.5% BBI in diet	<b>50% fewer tumors</b> <b>90-100% fewer tumors</b>	[10, 6] [10, 6]
	Min Mice (Colon cancer)	Genetic susceptibility	0.1% BBI in diet 0.5% BBI in diet	<b>30% fewer tumors</b> <b>40% fewer tumors</b>	[30] [30]
	Lung cancer	3-MC	10 mg/kg injected BBI	<b>30% fewer tumors</b>	[44]
	Human prostate Cancer	Xenograft	1% BBI in diet	<b>Reduced tumor load</b>	[40]
	Human pancreas cancer	Xenograft	1 mg/kg/day PCI injected	<b>70% less tumor volume</b>	[8]
Rat	Esophagus cancer	MBNA	180 mg BBI tablets	<b>40% fewer tumors</b>	[28]
	Mammary gland cancer	Chemical, X-ray	Soybean diet,	<b>Significant reduction</b>	[32]
	Irritable bowel disease	Dextrane sulphate	0.5% BBI	<b>15% less mortality</b> <b>significant reduction of symptoms</b>	[18]
Hamster	Oral cancer	DMBA	1% BBI in diet 0.001%	<b>80% fewer tumors</b> <b>60% fewer tumors</b>	[28] [28]
Human	Oral leuko-plakia	Smokers and alcoholics	Daily dose BBI for 1 month	<b>Reduced neu-oncogene expression</b>	[41]
	Oral leuko-plakia	Smokers and alcoholics	Daily dose BBI for 1 month	<b>24% reduced lesion size</b>	[2]
	PSA	Elder men	Daily dose BBI for 1 month	<b>Significant reduction (up to 43%)</b>	[35]
	Prostate volume	Elder men	Daily dose BBI for 1 month	<b>Significant volume reduction</b>	[35]


# Purification scheme of BBI from white lupin seeds

Step	µg prot/g seed	TIU/g seed	TIU/mg prot	Purification fold	Protein yield (%)	Activity yield (%)
Aqueous extract	183,100	12,705	69	1.0	100	100
Thermal-treated extract	910	169	186	2.7	0.50	1.32
DEAE-cellulose	148	150	1,029	14.9	0.076	1.18
TAC	4.0	112	28,370	411.1	0.022	0.88

# MALDI-TOF mass spectrum of LaBBI



# Alignment of legume seed double trypsin BBI amino acid sequences



Phytochemistry 69 (2008) 1820–1825

Contents lists available at ScienceDirect

Phytochemistry

journal homepage: [www.elsevier.com/locate/phytochem](http://www.elsevier.com/locate/phytochem)




## Identification and characterization of a Bowman–Birk inhibitor active towards trypsin but not chymotrypsin in *Lupinus albus* seeds

Alessio Scarafoni<sup>a,\*</sup>, Alessandro Consonni<sup>a</sup>, Valerio Galbusera<sup>a</sup>, Armando Negri<sup>b</sup>, Gabriella Tedeschi<sup>b</sup>, Patrizia Rasmussen<sup>a</sup>, Chiara Magni<sup>a</sup>, Marcello Duranti<sup>a</sup>


<sup>a</sup> Department of Agri-Food Molecular Sciences, State University of Milan, via G. Celoria 2, 20133 Milano, Italy

<sup>b</sup> Department of Animal Pathology, Hygiene and Veterinary Public Health-Section of Biochemistry, State University of Milan, via G. Celoria 10, 20133 Milano, Italy

# Titration curve of LaBBI with trypsin



# Predicted 3D structure of LaBBI





Based on snail medic seed  
(*Med. scutellata*, L.) BBI  
structure (1mvz):

*Seq. Id.: 78%*

*E value:  $2.6 \times 10^{-10}$*

# Comparison of the 3D structures of lentil (2AIH), pea (1PBI), soybean (1BBI) with lupin BBI



# Examples of biologically active legume seed proteins

<i>Protein family</i>	<i>Examples</i>	<i>Type of protein</i>	<i>Source</i>	<i>Adverse activity</i>	<i>Beneficial activity</i>
Proteinase inhibitors	BBI	Small, compact	Many seeds	Inhibition of endogenous proteolytic enzymes	Anticarcinogenic, anti-inflammatory
Amylase inhibitors	2S albumin	Small	Many seeds	Inhibition of endogenous amylolytic enzymes	Anti-obesity, diabetes, metabolic syndrome
Storage proteins	Conglycinin $\alpha'$ subunit	Large chain	Soybean	Not applicable	Hypolipidemic
	Gamma conglutin	Large chain	Lupin	Not applicable	Hypoglycemic
	Vicilin	Fragment	Lupin	Not applicable	Lectin
Lectins	PHA	Medium size	Many legume seeds	Hemagglutination	Immuno-modulation
Peptides	ACEIn	Small	Few seeds	Not known	Hypotensive
Thiamine BP	PA2	Small	Many seed	Not applicable	Vitamin vehiculation

# Currently available patents related to lupin seed protein nutraceuticals

- THE USE OF LUPIN CONGLUTIN FOR THE TREATMENT OF TYPE II DIABETES (WO2004071521)
- A RECENTLY SUBMITTED ITALIAN PATENT ON THE INSULIN-MIMETIC ACTIVITY OF  $\gamma$ -CONGLUTIN
- PASTA ENRICHED WITH VEGETABLE PROTEINS (EP0997078)
- A NUMBER OF PATENTS ON DEMONSTRATED EFFECTS OF BBIs

# Concluding remarks

1. **Molecular nutraceuticals** (of food proteins) is an intrinsically reductionist approach...

...however, system simplification is required for:

- ❖ **identifying** the responsible molecules
- ❖ **understanding** the effects and mechanisms
- ❖ **optimising** the exploitation strategies

2. **Synergies and antagonisms** between components are likely to occur in the whole food systems

3. Diseases involved are generally **multifactorial**

4. Many fundamental aspects are still open and require **basic research**

# Acknowledgements

## **DISMA team (protein purification and analysis):**

Jessica Capraro

Alessandro Consonni

Chiara Magni

Alessandro Ronchi

Alessio Scarafoni

Fabio Sessa

## **Surface Plasmon Resonance:**

Marco Vanoni (UniMiB)

## **Cell studies:**

Mariarosa Lovati (UniMi)

Livio Luzi (UniMI, S. Raffaele Hosp.)

Alfonso Clemente (CSIC, Granada, Spain)

## **Mass spectrometry, a.a. sequencing:**

Luca Espen (UniMi)

Armando Negri (UniMi)

Gabriella Tedeschi (UniMi)

## **Industrial developments and private grants:**

Paolo Morazzoni (INDENA, MI)

Andrea Budelli (PLADA, Heinz Group, MI)